Enliven Therapeutics Net Debt Growth & History (ELVN)
Enliven Therapeutics's net debt was −$98.5M for fiscal 2025.
View full Enliven Therapeutics company overviewEnliven Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$98.5M | $25.6M | — |
| 2024 | 2024-12-31 | −$124.1M | −$24.3M | — |
| 2023 | 2023-12-31 | −$99.8M | −$24.6M | — |
| 2022 | 2022-12-31 | −$75.2M | −$27.6M | — |
| 2021 | 2021-12-31 | −$47.7M | — | — |
Enliven Therapeutics quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$134.0M | −$15.1M | — |
| Q1 2026 | 2026-03-31 | −$131.9M | −$30.8M | — |
| Q4 2025 | 2025-12-31 | −$98.5M | — | — |
| Q3 2025 | 2025-09-30 | −$101.2M | −$706,000 | — |
| Q2 2025 | 2025-06-30 | −$118.9M | −$22.2M | — |
| Q1 2025 | 2025-03-31 | −$101.0M | $47.9M | — |
| Q3 2024 | 2024-09-30 | −$100.5M | −$27.1M | — |
| Q2 2024 | 2024-06-30 | −$96.7M | $28.5M | — |
| Q1 2024 | 2024-03-31 | −$148.9M | $142.6M | — |
| Q4 2023 | 2023-12-31 | −$99.8M | — | — |
| Q3 2023 | 2023-09-30 | −$73.4M | — | — |
| Q2 2023 | 2023-06-30 | −$125.2M | −$95.2M | — |
| Q1 2023 | 2023-03-31 | −$291.5M | −$257.5M | — |
| Q2 2022 | 2022-06-30 | −$30.0M | $17.3M | — |
| Q1 2022 | 2022-03-31 | −$34.0M | $18.6M | — |
| Q4 2021 | 2021-12-31 | −$47.7M | — | — |
| Q3 2021 | 2021-09-30 | −$74.6M | — | — |
| Q2 2021 | 2021-06-30 | −$47.3M | — | — |
| Q1 2021 | 2021-03-31 | −$52.6M | — | — |
Enliven Therapeutics net debt trends
Between the periods ended 2021-12-31 and 2025-12-31, Enliven Therapeutics's net debt decreased from −$47.7M to −$98.5M, a change of −$50.8M. The latest reported quarter, Q2 2026, shows −$134.0M.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Enliven Therapeutics source filings ↗